Does the media refer more to ACAD or REPL?

In the previous week, Replimune Group had 14 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 22 mentions for Replimune Group and 8 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 1.40 beat Replimune Group's score of 0.18 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ACADIA Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Replimune Group 3 Very Positive mention(s) 1 Positive mention(s) 17 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, DYN or REPL?

Dyne Therapeutics is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dyne Therapeutics N/A N/A -$446.21M -$3.33 N/A Replimune Group N/A N/A -$313.94M -$3.15 N/A

Is DYN or REPL more profitable?

Dyne Therapeutics' return on equity of -64.30% beat Replimune Group's return on equity. Company Net Margins Return on Equity Return on Assets Dyne Therapeutics N/A -64.30% -50.33% Replimune Group N/A -159.32% -90.84%

Does the media favor DYN or REPL?

In the previous week, Dyne Therapeutics had 2 more articles in the media than Replimune Group. MarketBeat recorded 24 mentions for Dyne Therapeutics and 22 mentions for Replimune Group. Dyne Therapeutics' average media sentiment score of 0.28 beat Replimune Group's score of 0.18 indicating that Dyne Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyne Therapeutics 10 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Replimune Group 3 Very Positive mention(s) 1 Positive mention(s) 17 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, CELC or REPL?

Celcuity is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Celcuity N/A N/A -$177.04M -$4.30 N/A Replimune Group N/A N/A -$313.94M -$3.15 N/A

Is CELC or REPL more profitable?

Replimune Group's return on equity of -159.32% beat Celcuity's return on equity. Company Net Margins Return on Equity Return on Assets Celcuity N/A -350.78% -41.54% Replimune Group N/A -159.32% -90.84%

Does the media favor CELC or REPL?

In the previous week, Replimune Group had 12 more articles in the media than Celcuity. MarketBeat recorded 22 mentions for Replimune Group and 10 mentions for Celcuity. Celcuity's average media sentiment score of 0.30 beat Replimune Group's score of 0.18 indicating that Celcuity is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celcuity 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Replimune Group 3 Very Positive mention(s) 1 Positive mention(s) 17 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is REPL or RLAY more profitable?

Relay Therapeutics' return on equity of -42.27% beat Replimune Group's return on equity. Company Net Margins Return on Equity Return on Assets Replimune Group N/A -159.32% -90.84% Relay Therapeutics N/A -42.27% -38.67%

Does the media prefer REPL or RLAY?

In the previous week, Relay Therapeutics had 2 more articles in the media than Replimune Group. MarketBeat recorded 24 mentions for Relay Therapeutics and 22 mentions for Replimune Group. Relay Therapeutics' average media sentiment score of 0.85 beat Replimune Group's score of 0.18 indicating that Relay Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Replimune Group 3 Very Positive mention(s) 1 Positive mention(s) 17 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Relay Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is REPL or TNGX more profitable?

Tango Therapeutics' return on equity of -25.75% beat Replimune Group's return on equity. Company Net Margins Return on Equity Return on Assets Replimune Group N/A -159.32% -90.84% Tango Therapeutics N/A -25.75% -23.36%

Does the media prefer REPL or TNGX?

In the previous week, Replimune Group had 5 more articles in the media than Tango Therapeutics. MarketBeat recorded 22 mentions for Replimune Group and 17 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 0.68 beat Replimune Group's score of 0.18 indicating that Tango Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Replimune Group 3 Very Positive mention(s) 1 Positive mention(s) 17 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tango Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Replimune Group (REPL) Competitors

$14.77 +0.72 (+5.12%)

As of 08/21/2026 04:00 PM Eastern

Compare

REPL vs. ACAD, DYN, CELC, RLAY, and TNGX

Should you buy Replimune Group stock or one of its competitors? Replimune Group's main competitors and comparable companies include ACADIA Pharmaceuticals (ACAD), Dyne Therapeutics (DYN), Celcuity (CELC), Relay Therapeutics (RLAY), and Tango Therapeutics (TNGX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Replimune Group compare to ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Replimune Group (NASDAQ:REPL) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

ACADIA Pharmaceuticals has higher revenue and earnings than Replimune Group. Replimune Group is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$1.07B	4.74	$391M	$2.22	13.29
Replimune Group	N/A	N/A	-$313.94M	-$3.15	N/A

ACADIA Pharmaceuticals has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market. Comparatively, Replimune Group has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market.

ACADIA Pharmaceuticals has a net margin of 33.42% compared to Replimune Group's net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 9.03% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%
Replimune Group	N/A	-159.32%	-90.84%

ACADIA Pharmaceuticals presently has a consensus target price of $34.19, indicating a potential upside of 15.91%. Replimune Group has a consensus target price of $11.86, indicating a potential downside of 19.72%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe ACADIA Pharmaceuticals is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.82
Replimune Group	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60

In the previous week, Replimune Group had 14 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 22 mentions for Replimune Group and 8 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 1.40 beat Replimune Group's score of 0.18 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Replimune Group	3 Very Positive mention(s)	1 Positive mention(s)	17 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.5% of Replimune Group shares are owned by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are owned by insiders. Comparatively, 5.4% of Replimune Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

ACADIA Pharmaceuticals beats Replimune Group on 13 of the 16 factors compared between the two stocks.

How does Replimune Group compare to Dyne Therapeutics?

Dyne Therapeutics (NASDAQ:DYN) and Replimune Group (NASDAQ:REPL) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

In the previous week, Dyne Therapeutics had 2 more articles in the media than Replimune Group. MarketBeat recorded 24 mentions for Dyne Therapeutics and 22 mentions for Replimune Group. Dyne Therapeutics' average media sentiment score of 0.28 beat Replimune Group's score of 0.18 indicating that Dyne Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dyne Therapeutics	10 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Replimune Group	3 Very Positive mention(s)	1 Positive mention(s)	17 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dyne Therapeutics has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market. Comparatively, Replimune Group has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market.

96.7% of Dyne Therapeutics shares are held by institutional investors. Comparatively, 92.5% of Replimune Group shares are held by institutional investors. 9.5% of Dyne Therapeutics shares are held by company insiders. Comparatively, 5.4% of Replimune Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Dyne Therapeutics is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.33	N/A
Replimune Group	N/A	N/A	-$313.94M	-$3.15	N/A

Dyne Therapeutics currently has a consensus price target of $34.42, suggesting a potential upside of 31.86%. Replimune Group has a consensus price target of $11.86, suggesting a potential downside of 19.72%. Given Dyne Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Dyne Therapeutics is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.87
Replimune Group	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60

Dyne Therapeutics' return on equity of -64.30% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-64.30%	-50.33%
Replimune Group	N/A	-159.32%	-90.84%

Summary

Dyne Therapeutics beats Replimune Group on 11 of the 14 factors compared between the two stocks.

How does Replimune Group compare to Celcuity?

Celcuity (NASDAQ:CELC) and Replimune Group (NASDAQ:REPL) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

63.3% of Celcuity shares are held by institutional investors. Comparatively, 92.5% of Replimune Group shares are held by institutional investors. 13.3% of Celcuity shares are held by insiders. Comparatively, 5.4% of Replimune Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Celcuity has a beta of 0.2, meaning that its stock price is 80% less volatile than the broader market. Comparatively, Replimune Group has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market.

Celcuity is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celcuity	N/A	N/A	-$177.04M	-$4.30	N/A
Replimune Group	N/A	N/A	-$313.94M	-$3.15	N/A

Replimune Group's return on equity of -159.32% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celcuity	N/A	-350.78%	-41.54%
Replimune Group	N/A	-159.32%	-90.84%

In the previous week, Replimune Group had 12 more articles in the media than Celcuity. MarketBeat recorded 22 mentions for Replimune Group and 10 mentions for Celcuity. Celcuity's average media sentiment score of 0.30 beat Replimune Group's score of 0.18 indicating that Celcuity is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celcuity	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Replimune Group	3 Very Positive mention(s)	1 Positive mention(s)	17 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Celcuity presently has a consensus target price of $154.55, suggesting a potential upside of 65.24%. Replimune Group has a consensus target price of $11.86, suggesting a potential downside of 19.72%. Given Celcuity's stronger consensus rating and higher possible upside, analysts clearly believe Celcuity is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celcuity	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Replimune Group	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60

Summary

Celcuity and Replimune Group tied by winning 7 of the 14 factors compared between the two stocks.

How does Replimune Group compare to Relay Therapeutics?

Replimune Group (NASDAQ:REPL) and Relay Therapeutics (NASDAQ:RLAY) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation.

Relay Therapeutics' return on equity of -42.27% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Replimune Group	N/A	-159.32%	-90.84%
Relay Therapeutics	N/A	-42.27%	-38.67%

Replimune Group presently has a consensus price target of $11.86, indicating a potential downside of 19.72%. Relay Therapeutics has a consensus price target of $25.92, indicating a potential upside of 33.32%. Given Relay Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Relay Therapeutics is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Replimune Group	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60
Relay Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93

92.5% of Replimune Group shares are owned by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are owned by institutional investors. 5.4% of Replimune Group shares are owned by company insiders. Comparatively, 5.0% of Relay Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Relay Therapeutics has higher revenue and earnings than Replimune Group. Relay Therapeutics is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Replimune Group	N/A	N/A	-$313.94M	-$3.15	N/A
Relay Therapeutics	$15.35M	277.53	-$276.48M	-$1.57	N/A

In the previous week, Relay Therapeutics had 2 more articles in the media than Replimune Group. MarketBeat recorded 24 mentions for Relay Therapeutics and 22 mentions for Replimune Group. Relay Therapeutics' average media sentiment score of 0.85 beat Replimune Group's score of 0.18 indicating that Relay Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Replimune Group	3 Very Positive mention(s)	1 Positive mention(s)	17 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Relay Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Replimune Group has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market. Comparatively, Relay Therapeutics has a beta of 1.69, suggesting that its share price is 69% more volatile than the broader market.

Summary

Relay Therapeutics beats Replimune Group on 13 of the 15 factors compared between the two stocks.

How does Replimune Group compare to Tango Therapeutics?

Replimune Group (NASDAQ:REPL) and Tango Therapeutics (NASDAQ:TNGX) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.

Replimune Group presently has a consensus price target of $11.86, indicating a potential downside of 19.72%. Tango Therapeutics has a consensus price target of $43.46, indicating a potential upside of 82.00%. Given Tango Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Tango Therapeutics is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Replimune Group	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

Tango Therapeutics' return on equity of -25.75% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Replimune Group	N/A	-159.32%	-90.84%
Tango Therapeutics	N/A	-25.75%	-23.36%

In the previous week, Replimune Group had 5 more articles in the media than Tango Therapeutics. MarketBeat recorded 22 mentions for Replimune Group and 17 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 0.68 beat Replimune Group's score of 0.18 indicating that Tango Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Replimune Group	3 Very Positive mention(s)	1 Positive mention(s)	17 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tango Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Tango Therapeutics has higher revenue and earnings than Replimune Group. Tango Therapeutics is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Replimune Group	N/A	N/A	-$313.94M	-$3.15	N/A
Tango Therapeutics	$62.38M	64.55	-$101.59M	-$0.85	N/A

92.5% of Replimune Group shares are held by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are held by institutional investors. 5.4% of Replimune Group shares are held by company insiders. Comparatively, 6.5% of Tango Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Replimune Group has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.16, suggesting that its stock price is 16% more volatile than the broader market.

Summary

Tango Therapeutics beats Replimune Group on 11 of the 15 factors compared between the two stocks.

Get Replimune Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding REPL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

REPL vs. The Competition

Export

Metric	Replimune Group	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.39B	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	11.08%
P/E Ratio	-4.69	11.62	272.88	24.24
Price / Sales	N/A	1,338.17	618.96	99.81
Price / Cash	N/A	105.14	78.62	53.99
Price / Book	13.07	16.80	13.05	6.20
Net Income	-$313.94M	-$12.50M	$3.47B	$348.59M
7 Day Performance	-1.34%	3.29%	2.09%	0.08%
1 Month Performance	41.20%	8.23%	6.64%	3.88%
1 Year Performance	160.49%	55.05%	25.02%	16.98%

Replimune Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
REPL Replimune Group	1.7649 of 5 stars	$14.77 +5.1%	$11.86 -19.7%	+160.5%	$1.39B	N/A	N/A	210	Earnings Report Insider Trade
ACAD ACADIA Pharmaceuticals	4.3251 of 5 stars	$28.19 -0.7%	$33.69 +19.5%	+14.6%	$4.85B	$1.07B	12.69	510	Positive News
DYN Dyne Therapeutics	3.3974 of 5 stars	$25.49 -1.8%	$34.42 +35.0%	+107.5%	$4.76B	N/A	N/A	100	Analyst Revision
CELC Celcuity	3.4037 of 5 stars	$95.19 +9.9%	$153.64 +61.4%	+78.4%	$4.59B	N/A	N/A	40
RLAY Relay Therapeutics	3.3876 of 5 stars	$19.75 -0.9%	$25.58 +29.6%	+426.8%	$4.32B	$15.35M	N/A	330	Trending News Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:REPL) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Replimune Group (REPL) Competitors

REPL vs. ACAD, DYN, CELC, RLAY, and TNGX

How does Replimune Group compare to ACADIA Pharmaceuticals?

Summary

How does Replimune Group compare to Dyne Therapeutics?

Summary

How does Replimune Group compare to Celcuity?

Summary

How does Replimune Group compare to Relay Therapeutics?

Summary

How does Replimune Group compare to Tango Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

REPL vs. The Competition

Replimune Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Replimune Group (REPL) Competitors

REPL vs. ACAD, DYN, CELC, RLAY, and TNGX

How does Replimune Group compare to ACADIA Pharmaceuticals?

Which has better valuation & earnings, ACAD or REPL?

Which has more risk & volatility, ACAD or REPL?

Is ACAD or REPL more profitable?

Do analysts rate ACAD or REPL?

Does the media refer more to ACAD or REPL?

Do institutionals and insiders have more ownership in ACAD or REPL?

Summary

How does Replimune Group compare to Dyne Therapeutics?

Does the media favor DYN or REPL?

Which has more volatility and risk, DYN or REPL?

Do insiders & institutionals hold more shares of DYN or REPL?

Which has better valuation and earnings, DYN or REPL?

Do analysts rate DYN or REPL?

Is DYN or REPL more profitable?

Summary

How does Replimune Group compare to Celcuity?

Do insiders and institutionals hold more shares of CELC or REPL?

Which has more volatility & risk, CELC or REPL?

Which has higher earnings & valuation, CELC or REPL?

Is CELC or REPL more profitable?

Does the media favor CELC or REPL?

Do analysts rate CELC or REPL?

Summary

How does Replimune Group compare to Relay Therapeutics?

Is REPL or RLAY more profitable?

Do analysts rate REPL or RLAY?

Do institutionals & insiders have more ownership in REPL or RLAY?

Which has higher valuation & earnings, REPL or RLAY?

Does the media prefer REPL or RLAY?

Which has more volatility and risk, REPL or RLAY?

Summary

How does Replimune Group compare to Tango Therapeutics?

Do analysts prefer REPL or TNGX?

Is REPL or TNGX more profitable?

Does the media prefer REPL or TNGX?

Which has higher valuation and earnings, REPL or TNGX?

Do institutionals and insiders have more ownership in REPL or TNGX?

Which has more risk and volatility, REPL or TNGX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

REPL vs. The Competition

Replimune Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools